These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11738102)

  • 1. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B.
    Kweon YO; Goodman ZD; Dienstag JL; Schiff ER; Brown NA; Burchardt E; Schoonhoven R; Brenner DA; Fried MW
    J Hepatol; 2001 Dec; 35(6):749-55. PubMed ID: 11738102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation.
    Carpino G; Morini S; Ginanni Corradini S; Franchitto A; Merli M; Siciliano M; Gentili F; Onetti Muda A; Berloco P; Rossi M; Attili AF; Gaudio E
    Dig Liver Dis; 2005 May; 37(5):349-56. PubMed ID: 15843085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine. A review of its therapeutic potential in chronic hepatitis B.
    Jarvis B; Faulds D
    Drugs; 1999 Jul; 58(1):101-41. PubMed ID: 10439933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamivudine as initial treatment for chronic hepatitis B in the United States.
    Dienstag JL; Schiff ER; Wright TL; Perrillo RP; Hann HW; Goodman Z; Crowther L; Condreay LD; Woessner M; Rubin M; Brown NA
    N Engl J Med; 1999 Oct; 341(17):1256-63. PubMed ID: 10528035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.
    Lai CL; Chien RN; Leung NW; Chang TT; Guan R; Tai DI; Ng KY; Wu PC; Dent JC; Barber J; Stephenson SL; Gray DF
    N Engl J Med; 1998 Jul; 339(2):61-8. PubMed ID: 9654535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A study on the clinical and pathological efficacy of lamivudine in the treatment of chronic hepatitis B].
    Yang C; Xiao YH; Guan XQ; Yuan Z
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):364-7. PubMed ID: 15225436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
    Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
    World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in serological biomarkers of liver function and connective tissue turnover in chronic hepatitis B during lamivudine therapy.
    Maxwell PR; Flisiak R
    Biomarkers; 2005; 10(6):475-84. PubMed ID: 16308271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.
    van Zonneveld M; Zondervan PE; Cakaloglu Y; Simon C; Akarca US; So TM; Flink HJ; de Man RA; Schalm SW; Janssen HL;
    Liver Int; 2006 May; 26(4):399-405. PubMed ID: 16629642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.
    Tatulli I; Francavilla R; Rizzo GL; Vinciguerra V; Ierardi E; Amoruso A; Panella C; Francavilla A
    J Hepatol; 2001 Dec; 35(6):805-10. PubMed ID: 11738109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
    Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
    Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrasting patterns of response to lamivudine monotherapy in chronic hepatitis B patients.
    Wolters LM; van Nunen AB; Niesters HG; de Man RA
    Scand J Gastroenterol Suppl; 2000; (232):74-8. PubMed ID: 11232497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection.
    Suzuki Y; Kumada H; Ikeda K; Chayama K; Arase Y; Saitoh S; Tsubota A; Kobayashi M; Koike M; Ogawa N; Tanikawa K
    J Hepatol; 1999 May; 30(5):743-8. PubMed ID: 10365796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of lamivudine in the therapy of Nigerian patients with Chronic HBV infection.
    Ola SO; Udo UA; Ogunrin AO
    Niger Postgrad Med J; 2014 Dec; 21(4):294-8. PubMed ID: 25633447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The concentration of Fas in the serum and liver tissue in viral chronic hepatitis B patients treated with lamivudine.
    Lapinski TW
    Hepatogastroenterology; 2005; 52(62):575-9. PubMed ID: 15816481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological outcome during long-term lamivudine therapy.
    Dienstag JL; Goldin RD; Heathcote EJ; Hann HW; Woessner M; Stephenson SL; Gardner S; Gray DF; Schiff ER
    Gastroenterology; 2003 Jan; 124(1):105-17. PubMed ID: 12512035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Liver histological changes after lamivudine treating in chronic hepatitis B patients with HBeAg positive].
    Jin RH; Lang ZW; Yao GB; Guo XH
    Zhonghua Gan Zang Bing Za Zhi; 2003 Sep; 11(9):555-7. PubMed ID: 14552720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome after portoenterostomy in biliary atresia: pivotal role of degree of liver fibrosis and intensity of stellate cell activation.
    Shteyer E; Ramm GA; Xu C; White FV; Shepherd RW
    J Pediatr Gastroenterol Nutr; 2006 Jan; 42(1):93-9. PubMed ID: 16385261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunohistochemical analysis of alpha-SMA and GFAP expression in liver stellate cells].
    Tomanović N; Boricić I; Brasanac D
    Vojnosanit Pregl; 2006 Jun; 63(6):553-7. PubMed ID: 16796020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
    Tassopoulos NC; Volpes R; Pastore G; Heathcote J; Buti M; Goldin RD; Hawley S; Barber J; Condreay L; Gray DF
    Hepatology; 1999 Mar; 29(3):889-96. PubMed ID: 10051494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.